BioPharma Drive: Drug Pricing

JULY 3, 2024

Multibillion-dollar buyouts from Bristol Myers Squibb and Gilead could yield new drugs for brain and liver diseases, while a new cell therapy may reach market.

FDA 317

FDA Therapies Disease Marketing 317

BioPharma Drive: Drug Pricing

MAY 13, 2024

Goldman Sachs and Eli Lilly are among those backing the startup, which claims its prospect could be more potent than the myelofibrosis therapies that have come to market in recent years.

Therapies 329

Therapies Marketing Drugs 329

Conversations in Drug Development Trends

NOVEMBER 12, 2024

By Amy Raymond, PhD, PMP, Executive Director, Therapeutic Strategy Lead, Rare Disease Cell and gene therapies (CGTs) include cutting-edge approaches that offer the hope of a healthier, happier, and better tomorrow for a wide range of patient populations. Below, we discuss some of these challenges in cell therapy trials.

Therapies 72

Therapies Clinical Supply Clinical Trials Trials 72

BioPharma Drive: Drug Pricing

OCTOBER 10, 2024

Data readouts over the next six months could set expectations for how the highly lucrative market for weight loss therapies will look in the future.

Trials 273

Trials Therapies Marketing 273

BioPharma Drive: Drug Pricing

MARCH 20, 2024

million list price, the highest of any genetic medicine to come to market. Orchard is counting on the long-term data it’s accrued to convince insurers to cover Lenmeldy’s $4.25

Therapies 205

Therapies Marketing 205

Drug Target Review

APRIL 30, 2025

In the rapidly evolving field of cell and gene therapy (CGT), the ability to manage complex biological data, optimise manufacturing processes, and accelerate drug discovery is crucial. How AI is solving CGTs biggest challenges Cell and gene therapy is inherently complex. Faster time-to-market and reduced costs. The result?

Drugs 90

Drugs Therapies Clinical Trials Trials 90

Drug Patent Watch

JANUARY 13, 2025

As we delve into the intricate world of biosimilar market dynamics, we’ll explore how these complex molecules are reshaping treatment paradigms across diverse patient populations. ”[1] The global biosimilars market is experiencing exponential growth, with projections indicating it will reach $69.4 from 2020 to 2025[1].

Biosimilars 58

Biosimilars Marketing Treatment Small Molecule 58

The Pharma Data

JUNE 13, 2025

Standard single-target CD19-directed CAR T-cell therapies typically enable long-term remissions in roughly 40% of patients, emphasizing a significant unmet need for new and more effective treatment strategies. Among patients who had previously undergone two or more lines of therapy (n = 12), the ORR was 92% and the CRR was 75%.

Therapies 40

Therapies Treatment Clinical Development Trials 40

Drug Target Review

NOVEMBER 8, 2023

Problem w/ CTs and foundational understanding of Vittoria: can you explore the current limitations of cell therapies and the challenges faced by patients and providers? Currently, only a small percentage of cancers can be effectively treated with cell therapies, and there is little diversity in the currently approved products.

Therapies 116

Therapies Engineering Treatment Molecular Biology 116

Drug Target Review

JUNE 9, 2025

“This experience underscored the gaps in rare disease innovation, motivating me to lead Alltrna, a company pioneering engineered tRNA therapies to address a broad range of genetic diseases in a profound way unlike any other genetic modality.”

Disease 80

Disease Treatment Engineering Protein Production 80

BioPharma Drive: Drug Pricing

MAY 6, 2024

One analyst thinks the collaboration “bodes well” for Gossamer, which has had trouble convincing investors its drug seralutinib can compete on the market.

Therapies 176

Therapies Drugs Marketing 176

BioPharma Drive: Drug Pricing

OCTOBER 23, 2024

Elsewhere, Sangamo plotted a much faster path to market for its Fabry gene therapy. Yale spinout Modifi agreed to sell to Merck for $30 million upfront.

Therapies 190

Therapies Marketing Drugs 190

Drug Target Review

JANUARY 4, 2024

What distinguishes Alder Therapeutics’ approach to regenerative cell therapy development from traditional methods, and how does it aim to reduce risks in the preclinical phase? Traditional approaches to regenerative cell therapy development are defined by several challenges. For manufacturing, it’s no different.

Therapies 98

Therapies Small Molecule Production Disease 98

PPD

OCTOBER 17, 2024

Cell and gene therapy (CGT) studies are rapidly gaining momentum in the Asia-Pacific region, fueled by growing patient demand and a thriving ecosystem of innovation. In China, the high incidence of solid tumors is driving an urgent need for advanced therapies, spurring the push for new treatment approaches.

Therapies 97

Therapies Clinical Trials Clinical Research Trials 97

BioPharma Drive: Drug Pricing

DECEMBER 10, 2023

While new gene therapies for the blood disease grabbed headlines at ASH, Pfizer presented fresh data for an oral drug meant to build on its marketed therapy Oxbryta.

Drugs 190

Drugs Therapies Disease Marketing 190

BioPharma Drive: Drug Pricing

JULY 3, 2024

Elsewhere, Vertex got an FDA decision date for its “vanza triple” and Dupixent won a marketing green light in Europe for COPD. Forbion led the startup’s Series B round.

Therapies 150

Therapies FDA Marketing 150

BioPharma Drive: Drug Pricing

APRIL 9, 2025

market, bladder cancer treatment Adstiladrin earned about $77 million. In its first full year on the U.S. Elsewhere, Lilly backed a cancer drug startup and Bristol Myers won a new Opdivo approval.

Therapies 144

Therapies Treatment Marketing Drugs 144

Chemical Biology and Drug Design

MAY 10, 2025

Although it is currently only used in veterinary therapy, carprofen proves to be a molecule with a versatile therapeutic potential for human pharmacotherapy. Moreover, the molecule is a target in the drug discovery process for the development of new bioactive compounds.

Small Molecule 100

Small Molecule Drug Development Science Therapies 100

Drug Target Review

DECEMBER 4, 2024

Confo Therapeutics , led by CEO Dr Cedric Ververken, is at the forefront of developing innovative GPCR-targeted therapies using its proprietary ConfoBody ® platform. VHH-based therapies have been clinically-validated many times with multiple products in numerous indications, including for long-term dosing.

Small Molecule 122

Small Molecule Pharmacokinetics Therapies Immune Response 122

BioPharma Drive: Drug Pricing

SEPTEMBER 24, 2024

The announced job cuts are the latest in a series of steps Bluebird has taken to preserve cash and break even financially amid slow uptake of its marketed gene therapies.

Therapies 167

Therapies Marketing 167

ASPET

OCTOBER 20, 2023

However, Pramlintide an adjunct to insulin therapy, enhances glucagon suppression and thereby offers improved glycaemic control. Although clinical benefits of Pramlintide are well reported, there still exists a high patient resistance for the therapy as separate injections for Pramlintide and insulin are required to be administered.

Therapies 100

Therapies Pharmacokinetics Treatment Marketing 100

Drug Target Review

MAY 21, 2025

In an era where biotherapeutics are transforming the healthcare landscape, the organisation, Vitalant , is uniquely positioned to bridge the gap between cutting-edge therapies and community access. Building new services and treatment options for patients are a passion for me.

Therapies 52

Therapies Hospitals Production Treatment 52

Drug Channels

MARCH 28, 2024

Bill discusses specialty therapy access barriers, including payer utilization management techniques and “no coverage” policies. Today’s guest post comes from Bill Dupere, SVP of Product Development & Partnerships at Mercalis. Contact Mercalis to learn about their Patient Support Services. Read on for Bill’s insights.

Marketing 98

Marketing Science Therapies Production 98

PPD

NOVEMBER 11, 2024

As a result, biopharma and biotech companies working to bring their drug pipelines to the market require deep expertise from trusted partners to help deliver critical therapies for their patients. billion in 2023 to 1.2 billion in 2035.

Drug Development 97

Drug Development Clinical Trials Drugs Small Molecule 97

FDA Law Blog: Drug Discovery

DECEMBER 6, 2024

Valentine On November 19, 2024, FDA released a draft guidance titled Frequently Asked Questions Developing Potential Cellular and Gene Therapy Products. The draft guidance states that only one 90-minute pre-BLA meeting will typically be granted for a specific product or indication planned for an original marketing application.

Therapies 59

Therapies FDA Production Disease 59

BioPharma Drive: Drug Pricing

SEPTEMBER 18, 2024

The FDA’s clearance could double Kisqali’s breast cancer market. Elsewhere, Novo is exploring new ways to deliver genetic therapies and Bain is funding a growing CDMO.

FDA 144

FDA Therapies Marketing 144

BioPharma Drive: Drug Pricing

JANUARY 31, 2024

The gene therapy developer’s demise has given Tectonic Therapeutic, a GPCR-focused startup founded by the prolific biotech entrepreneur, an alternate path to the public markets.

Therapies 157

Therapies Marketing 157

Drug Target Review

JUNE 19, 2024

The mission of Lineage Cell Therapeutics is to deliver on some of the early promises of cell therapy. Cell therapy as a concept is a wonderful idea, but many of the early efforts never generated the kind of clinical data that gets people excited and leads to new medicines. In some cases, cell therapy can be curative for the patient.

Therapies 84

Therapies Small Molecule Pharmaceutical Companies Molecular Biology 84

Drug Target Review

JUNE 5, 2025

Despite recent advances in gene therapy for sickle cell disease (SCD) , automated red blood cell exchange (aRBCX) remains a cornerstone therapy that plays a vital yet underutilised role in managing complications and enhancing quality of life for millions living with this devastating condition worldwide.

Disease 52

Disease Treatment Therapies Nurses 52

Fierce BioTech

SEPTEMBER 24, 2024

Unlocking European market access for rare disease therapies The European orphan drug market presents a significant opportunity for biotech firms. Learn more about early access programs (EAPs), and how they are emerging as a critical strategy for successfully launching rare disease therapies in this complex and diverse market.

Marketing 40

Marketing Therapies Disease Drugs 40

PPD

JANUARY 15, 2025

Accelerate customer speed to market With a modern and integrated user experience, AI solutions put the right data and insights into the right hands in real time. As a result, drug developers make better decisions more quickly (removing 50% of study timeline whitespace) to bring new therapies to market faster.

Clinical Trials 95

Clinical Trials Trials Clinical Research Drug Development 95

LifeSciVC

NOVEMBER 28, 2023

Market conditions like this are demoralizing in the worst way. Furthermore, to make matters even more complicated, that same summer, markets had already turned sour, and the sentiment was darkening by the day. The biotech equity markets had effectively shut off the idea of an IPO (which was one of several paths we had mapped out).

Marketing 96

Marketing FDA Pharma Companies Government 96

Drug Target Review

APRIL 7, 2025

As our understanding of the underlying biology of disease grows more sophisticated, emerging therapies operate on increasingly complex biopathological systems and mechanisms. Safety biomarkers account for adverse effects of a therapy under study. There are several types of biomarkers to consider.

Clinical Development 69

Clinical Development Clinical Trials Clinical Pharmacology Trials 69

Fierce BioTech

JUNE 11, 2025

The biologics revolution is in full swing, and as innovation accelerates, so does the complexity of bringing these life-changing therapies to market. | The biologics revolution is in full swing, and as innovation accelerates, so does the complexity of bringing these life-changing therapies to market.

Therapies 52

Therapies International Science Marketing 52

The Pharma Data

JUNE 16, 2025

Teva and Fosun Pharma Forge Strategic Partnership to Develop and Commercialize Innovative Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology Teva Pharmaceutical Industries Ltd. TEV-56278 is a first-in-class anti-PD1-IL2 ATTENUKINE therapy designed by Teva’s internal team of innovative scientists.

40

40

Fierce BioTech

MARCH 15, 2024

Oncology Market Outlook 2024 This paper assesses the current state of the oncology market, reviewing key expectations for 2024. It addresses CAR-T therapies, KRAS, radiopharmaceuticals, & targeted protein degradation. It addresses CAR-T therapies, KRAS, radiopharmaceuticals, & targeted protein degradation.

Targeted Protein Degradation 52

Targeted Protein Degradation Marketing Therapies Science 52

The Pharma Data

JUNE 9, 2025

A Game-Changing Growth Hormone Therapy Lonapegsomatropin is a long-acting recombinant human growth hormone (rhGH) therapy designed to be administered once weekly. We are committed to not only strengthening this partnership but also expanding our collaborative horizon to bring more innovative therapies to patients across China.”

Therapies 40

Therapies Pharmaceuticals Production Treatment 40